Navigation Links
Myriad Genetics Presents Tumor Origin Technology at AACR

Determining Tumor Origin May Be Useful in Cancer Treatment Decisions

SALT LAKE CITY, UT, April 18, 2007--Myriad Genetics, Inc. (NASDAQ: MYGN) (www.myriad.com) announced today that it presented studies for a new technology that might be used to determine the original location of a metastatic tumor, on Monday, April 16, 2007 at the annual meeting of the American Association for Cancer Research (AACR) in Los Angeles, California. This work could also prove helpful in determining whether any two tumors are related, and was carried out in collaboration with researchers from Magee-Womens Hospital and the University of Pittsburgh Medical Center.

Tumor origin can play an important role in choosing among treatment options for cancer patients. A difficult problem in treating some gynecological malignancies is determining the primary site of tumor origin. This is particularly apparent when cancer simultaneously involves both the ovary and endometrium. Myriad has developed a technology based on DNA copy number analysis, which may be used to accurately distinguish between the different possible originating or primary tumors.

The preliminary data from Myriad's study came from patient specimens with diagnoses of simultaneous ovarian and endometrial cancers. Three separate specimens were collected and analyzed for DNA copy number from each patient, one from the ovarian tumor, one from the endometrial tumor and one from normal unaffected tissue.

In many cases, pathologists may be unable to distinguish between related tumors and separate primary tumors due to the uncertain nature of the pathology results. The copy number analysis either confirmed conclusions from pathological examination, or provided new information that could be used to give a more positive determination of tumor source. Copy number analysis can show that both tumors share a change
'"/>




Page: 1 2 3

Related medicine technology :

1. Myriad Genetics Presents Mathematical Comparison of Disease Modification Trial Designs at Alzheimers ConferenceCurrent Flurizan Phase 3 Study Design May Demonstrate Disease Modification
2. Myriad Genetics Presents Azixas Mode of Action at AACR
3. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
4. Genetics Journal Thimerosal/Autism Study the Best Science Drug Company Money Can Buy
5. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
6. ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial in B-Cell Chronic Lymphocytic Leukemia
7. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
8. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
9. Expression Genetics, Inc. Announces Successful Completion of Phase I Trial of Gene-Based IL-12 for Treatment of Ovarian Cancer
10. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Myriad Genetics Presents Tumor Origin Technology AACR
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... ... ... Throughout its 20 year history, Doctors on Liens has pioneered ... basis. As the personal injury and medical industries have changed, Doctors on Liens ... pain management physicians, to psychologists and more. And while many of these offices ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... respected water brands also made the organization’s list. As its name clearly indicates, 10 ... available. Here is a description of the top three brands, along with a listing ...
(Date:7/27/2015)... Dallas, Texas (PRWEB) , ... July 27, 2015 ... ... the use of fullerenes in medical and diagnostics applications is rapidly increasing and ... drug delivery and cancer treatment, they are increasingly being evaluated for use in ...
(Date:7/27/2015)... ... , ... Boston IVF, the first Massachusetts egg freezing center to assist in ... Nantucket Island for women who wish to learn more about their fertility and egg ... Chins Way, Nantucket Island 02554 from 4:30-6:30pm. , This casual and informative event will ...
(Date:7/27/2015)... ... 27, 2015 , ... Standifer Insurance Group, a locally owned insurance company with ... Conquest, a specialized camp for young people who have been hospitalized in the burn ... and four night curriculum designed to give burn survivors between the ages of 6-17 ...
Breaking Medicine News(10 mins):Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 3Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 2Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 3
... -- A common form of heart trouble called diastolic ... an increased risk of heart failure, new research shows. ... age, the heart,s left ventricle fills with blood in an ... The new study included more than 2,000 people aged ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) -- ... regular medications for chronic conditions during their stay and ... say. Patients treated in the intensive care unit ... medication schedule after discharge, probably because there are so ...
... chemicals can be like putting together a puzzle. University ... the pieces together to more efficiently build complex molecules, ... by chemistry professor Martin Burke, the team published its ... Angewandte Chemie . Burke,s group is known for ...
... researchers have proposed in a new study a different ... using data from other similar chemicals. For ... have enough information to understand all of the effects ... this, the European Union enacted the REACH regulation, which ...
... patients treated at a U.S. military hospital in Afghanistan ... in the September issue of Infection Control and ... Healthcare Epidemiology of America. The findings underscore the need ... both soldiers and local patients are treated, the study,s ...
... -- The amount of fighting and arguing in your marriage ... study suggests. Ohio State University researchers looked at data ... 2000. Based on how often participants said they disagreed with ... high-conflict marriages. There was little change in any of ...
Cached Medicine News:Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 3Health News:A new set of building blocks for simple synthesis of complex molecules 2Health News:Scientists develop new approaches to predict the environmental safety of chemicals 2Health News:Study: Afghan patients a common source of drug-resistant bacteria 2Health News:Couples Who Don't Fight Much Aren't Likely to Start 2
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: